Australia…One Hour In…ASX up 10 points

By Scott Phillips | More Articles by Scott Phillips

ASX200 up 10 points (0.1%) to 6707.

  • Acrux (+48%); the USFDA has approved its generic product based on Perrigo’s Testosterone Topical Solution.
  • Altium (-3.7%);  1H revenue fell by 3% on the impact of the Covid-19 pandemic, but has maintained full-year guidance amid what it said were signs of positive momentum.
  • ARB Corp (+5.5%);  1H revenue +21.6%.
  • Mesoblast (+3.9%);  Trial 3 results of Rexlemestrocel-L provide major breakthrough in reducing heart failure.  (Lots of medical terminology in the notice so please check before quoting me….)
  • PolyNovo (-6%);  1H sales soar 31%.       Oct/Nov sales were slow but December exceeded budget.
  • Pushpay (+5%); lifts earnings guidance on stronger than expected December volumes.
  • Sezzle (+6%); 4Q underlying merchant sales +205% on pcp.